Octavi Camps
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
NCT Number: NCT07694323
To evaluate longitudinal changes in oral health-related quality of life (OHRQoL) and other patient-reported outcomes (PROMs) throughout the different stages of peri-implantitis therapy, including diagnosis, non-surgical treatment, surgical treatment, and 6-month follow-up. Secondarily, to explore the influence of clinical, implant-related, and surgical factors on patient-reported outcomes and treatment experience.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Prospective multicenter observational cohort study conducted at three university centers: the University of Barcelona (coordinating center), the International University of Catalonia, and the University of Valencia.
Patients diagnosed with peri-implantitis and requiring surgical treatment will be consecutively recruited and followed through four evaluation time points:
T0: Diagnosis T1: Six weeks after non-surgical therapy T2: Six weeks after surgical treatment T3: Six-month follow-up
Primary objective:
To evaluate longitudinal changes in oral health-related quality of life (OHRQoL) throughout peri-implantitis therapy. OHRQoL will be assessed using a modified version of the OHIP-14 questionnaire specifically adapted for patients with peri-implantitis.
Secondary objectives:
To assess changes in patient-reported experience measures (PREMs), including pain, anxiety, emotional impact, satisfaction, functional limitations, aesthetic perception, and treatment expectations.
To investigate the association between patient-reported outcomes and clinical parameters such as probing depth, bleeding/suppuration on probing, peri-implant bone loss, tissue phenotype, and defect morphology.
To evaluate whether patient-reported outcomes differ according to the type of surgical treatment performed (access, resective, regenerative, or combined surgery).
To explore the influence of patient-, implant-, and prosthetic-related factors on treatment experience and quality of life outcomes.
At each study visit, participants will complete the patient-reported outcome questionnaire and undergo standardized clinical assessments. The study does not modify routine clinical care, and all treatments will be provided according to current clinical guidelines and clinician judgment. This study aims to provide novel evidence regarding the real-world patient experience throughout peri-implantitis therapy and to support a more patient-centered approach to peri-implant disease management.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
When previous records are unavailable, implants will be included if they present bleeding and/or suppuration on gentle probing, probing depth ≥6 mm, and a bone level ≥3 mm apical to the most coronal portion of the rough implant surface.
Exclusion criteria
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment)
Change in oral health-related quality of life throughout peri-implantitis treatment, assessed using the Spanish version of the Oral Health Impact Profile-14 (OHIP-14sp). The total OHIP-14sp score ranges from 0 to 56, with higher scores indicating worse oral health-related quality of life. The outcome will be expressed as the total OHIP-14sp score and compared across the four study time points.
Unit of Measure: OHIP-14sp total score (0-56)
Time frame: T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Pain perceived by the patient during each stage of peri-implantitis treatment, measured using a 100-mm visual analogue scale (VAS), where 0 indicates no pain and 100 indicates the worst imaginable pain Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Anxiety and concern perceived by the patient in relation to the diagnosis of peri-implantitis and its treatment, measured using a 100-mm visual analogue scale (VAS), where 0 indicates no anxiety or concern and 100 indicates the highest imaginable level of anxiety or concern.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Emotional impact perceived by the patient in relation to the diagnosis of peri-implantitis and its treatment, including feelings such as fear of implant loss and frustration with the diagnosis, measured using a 100-mm visual analogue scale (VAS), where 0 indicates no emotional impact and 100 indicates the highest imaginable emotional impact.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Patient satisfaction with the treatment received for peri-implantitis, measured using a 100-mm visual analogue scale (VAS), where 0 indicates no satisfaction and 100 indicates the highest possible level of satisfaction.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Patient-perceived oral function following peri-implantitis treatment, including the ability to chew, speak, and perform oral hygiene, measured using a 100-mm visual analogue scale (VAS), where 0 indicates complete functional impairment and 100 indicates normal oral function.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Patient perception of the extent to which the outcomes of peri-implantitis treatment met their initial expectations, measured using a 100-mm visual analogue scale (VAS), where 0 indicates that the treatment outcomes did not meet expectations at all and 100 indicates that the treatment outcomes completely met or exceeded expectations.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T2 (6 weeks after surgical treatment) and T3 (6 months after surgical treatment)
Patient perception of the aesthetic outcome following surgical treatment for peri-implantitis, measured using a 100-mm visual analogue scale (VAS), where 0 indicates complete dissatisfaction with the aesthetic outcome and 100 indicates complete satisfaction with the aesthetic outcome.
Unit of Measure: Millimeters (0-100 mm VAS)
Time frame: T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Depth of peri-implant sulcus measured at six sites per implant using standardized probing force (20-25 g). Unit of Measure: millimeters (mm)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Radiographic marginal bone level measured in millimeters as the distance from the implant reference point designed to be in intimate contact with the bone to the most coronal bone-to-implant contact on standardized periapical radiographs.
Unit of Measure: Millimeters (mm)
Time frame: T2 (during surgical treatment).
Peri-implant bone defect morphology classified according to the predominant defect configuration as intrabony, suprabony, or combined, based on the intraoperative clinical assessment.
Unit of Measure: Categorical (intrabony, suprabony, combined)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Distance from the mucosal margin to the mucogingival junction at the buccal aspect of the implant, measured using a periodontal probe.
Unit of Measure: Millimeters (mm)
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Thickness of the buccal keratinized peri-implant mucosa assessed using the periodontal probe transparency method. The mucosa is classified as thin if the periodontal probe is visible through the tissue (<1 mm) and thick if the probe is not visible (≥1 mm).
Unit of Measure: Categorical (thin [<1 mm] or thick [≥1 mm])
Time frame: T0 (baseline)
Participant age at baseline (T0), calculated as the interval between the date of birth and the enrollment date.
Unit of Measure: Years, months, and days
Time frame: Time Frame: T0 (baseline)
Self-reported sex of the participant, recorded at baseline. Unit of Measure: Categorical (Male, Female, Other, Prefer not to disclose)
Time frame: T0 (baseline)
Self-reported smoking status at baseline. Unit of Measure: Categorical (Never smoker, Former smoker, Current smoker)
Time frame: T0 (baseline)
Average number of cigarettes smoked per day, self-reported by current and former smokers.
Unit of Measure: Cigarettes/day
Time frame: T0 (baseline)
Presence of relevant systemic comorbidities based on the participant's self-reported medical history and clinical records.
Unit of Measure: Categorical (Yes/No)
Time frame: T0 (baseline)
Self-reported frequency of toothbrushing. Unit of Measure: Categorical (Once daily, Twice daily, Three or more times daily)
Time frame: T0 (baseline)
Type of toothbrush routinely used by the participant. Unit of Measure: Categorical (Manual, Electric, Both)
Time frame: T0 (baseline)
Primary method used by the participant for interproximal oral hygiene. Unit of Measure: Categorical (Dental floss, Interdental brushes, Oral irrigator, None)
Time frame: T0 (baseline)
Self-reported frequency of interproximal oral hygiene. Unit of Measure: Categorical (Never, Occasionally, Daily)
Time frame: T0 (baseline)
Primary reason for the loss of the tooth replaced by the implant, based on the participant's dental history and clinical records.
Unit of Measure: Categorical (Periodontitis, Caries, Endodontic failure, Root fracture, Trauma, Congenital absence, Orthodontic extraction, Other)
Time frame: T0 (baseline)
Arch in which the implant is located. Unit of Measure: Categorical (Maxilla, Mandible)
Time frame: T0 (baseline)
Anatomical position of the implant according to its location in the dental arch.
Unit of Measure: Categorical (Anterior, Posterior)
Time frame: T0 (baseline)
Specific tooth position replaced by the implant, recorded using the FDI tooth numbering system.
Unit of Measure: Tooth number
Time frame: T0 (baseline)
Commercial brand of the implant. Unit of Measure: Free text
Time frame: T0 (baseline)
Commercial model of the implant. Unit of Measure: Free text
Time frame: T0 (baseline)
Type of implant surface according to the manufacturer's specifications. Unit of Measure: Categorical (Treated, Untreated)
Time frame: T0 (baseline)
Type of implant-prosthetic connection. Unit of Measure: Categorical (Internal, External, Conical, Other)
Time frame: T0 (baseline)
Type of implant-supported restoration according to its retention mechanism. Unit of Measure: Categorical (Screw-retained, Cement-retained)
Time frame: T0 (baseline)
Calendar year in which the implant-supported prosthetic restoration was delivered and functionally loaded.
Unit of Measure: Year
Time frame: T0 (baseline)
Total number of dental implants present in the participant at baseline, recorded to account for patient-level clustering in statistical analyses.
Unit of Measure: Number of implants
Time frame: T0 (baseline)
Calendar year in which the implant was surgically placed. Unit of Measure: Year
Time frame: T0 (immediately after diagnosis), T1 (6 weeks after non-surgical treatment), T2 (6 weeks after surgical treatment), and T3 (6 months after surgical treatment).
Presence of bleeding and/or suppuration elicited within 30 seconds after gentle probing at six sites per implant using a standardized periodontal probe.
Unit of Measure: Categorical (Present/Absent)
Time frame: T2 (during surgical treatment)
Surgical approach used for the treatment of peri-implantitis, classified according to the primary surgical technique performed.
Unit of Measure: Categorical (Access surgery, Resective surgery, Regenerative surgery, Combined surgery)
Time frame: T2 (6 weeks after surgical treatment)
Presence of postoperative wound dehiscence at the surgical site, assessed during the postoperative clinical examination.
Unit of Measure: Categorical (Present/Absent)
Time frame: T2 (6 weeks after surgical treatment) and T3 (6 months after surgical treatment)
Occurrence of postoperative complications related to peri-implantitis surgery, including the type of complication when present.
Unit of Measure: Categorical (Absent/Present) and free text (type of complication)
Contact information is provided by the study sponsor or research team.
University of Barcelona
Other
Patient-Centered Outcomes Throughout Peri-Implantitis Therapy: A Multicenter Prospective Observational Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02671812
Behavior, Digestive System Diseases
View Trial DetailsNCT04749953
Behavior, Health Behavior
Aalborg, North Denmark, Denmark
View Trial DetailsNCT07697729
Mouth Diseases, Peri-Implantitis
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07032259
Mouth Diseases, Peri-Implantitis
View Trial Details